Pharmala Biotech Holdings Inc. (CSE:MDMA)

Canada flag Canada · Delayed Price · Currency is CAD
0.1000
-0.0050 (-4.76%)
Jan 20, 2026, 3:11 PM EST
-61.54%
Market Cap11.43M
Revenue (ttm)754.64K
Net Income (ttm)-2.11M
Shares Out108.89M
EPS (ttm)-0.02
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume379,489
Average Volume153,892
Open0.1050
Previous Close0.1050
Day's Range0.1000 - 0.1100
52-Week Range0.0850 - 0.2950
Beta0.77
RSI46.45
Earnings DateApr 29, 2026

About Pharmala Biotech Holdings

Pharmala Biotech Holdings Inc., a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headquartered in Vancouver, Canada. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Nicholas Kadysh
Country Canada
Stock Exchange Canadian Securities Exchange
Ticker Symbol MDMA
Full Company Profile

Financial Performance

In 2025, Pharmala Biotech Holdings's revenue was 605,498, a decrease of -41.51% compared to the previous year's 1.04 million. Losses were -2.18 million, 164.1% more than in 2024.

Financial Statements

News

There is no news available yet.